MedTrace Logo

Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer Patients

NCT01306188 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 179

Last updated 2015-07-02

No results posted yet for this study

Summary

The T and B cells repertoire diversity represent one of the immune defence level which controls the integrity of the organism and determines its ability to recognize and control infectious attacks and development of tumours. The study of the lymphocytes TCR and BCR diversity could permit to better understand how lymphopenia act on overall survival and to improve detection of high risk patients who could benefit of adapted therapies for better care.

Conditions

Interventions

BIOLOGICAL

Breast cancer cohort

Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study. For each patient, the following analyses is performed: * The analysis of TCR and BCR repertoire diversity, * The phenotypic analysis of immune subpopulations, * The analysis of the global lymphopenia or subpopulations T, * The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.

BIOLOGICAL

Lung cancer cohort

Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study. For each patient, the following analyses is performed: * The analysis of TCR and BCR repertoire diversity, * The phenotypic analysis of immune subpopulations, * The analysis of the global lymphopenia or subpopulations T, * The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.

Sponsors & Collaborators

  • The Biostatistics and Therapy Evaluation Unit

    collaborator OTHER

  • BEC (Department of Clinical Sciences)

    collaborator UNKNOWN

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Olivier TREDAN, MD · Centre Leon Berard

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01306188 on ClinicalTrials.gov